2.19
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
Best deals to access real time data! |
|
CHART Trader
Monthly Subscription
for only
|
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Marker Therapeutics Inc | MRKR | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.0% | 2.19 | 0.00 | 0.00 | 0.00 | 2.19 | 04:55:34 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 2.16 | 2.25 | 0.09 | 4.0% | - | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 2.19 | USD |
Marker Therapeutics Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 101.91M | 46.53M | 31.31M | $ 213.19k | $ - | -0.47 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Marker Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MRKR Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.50 | 2.66 | 2.09 | 2.23 | 494,520 | -0.31 | -12.4% |
| 1 Month | 2.36 | 2.94 | 2.08 | 2.46 | 632,130 | -0.17 | -7.2% |
| 3 Months | 2.00 | 3.22 | 1.33 | 2.27 | 505,999 | 0.19 | 9.5% |
| 6 Months | 3.20 | 3.43 | 1.33 | 2.51 | 400,540 | -1.01 | -31.56% |
| 1 Year | 5.56 | 9.17 | 1.33 | 4.24 | 437,149 | -3.37 | -60.61% |
| 3 Years | 10.01 | 10.25 | 1.33 | 4.78 | 382,291 | -7.82 | -78.12% |
| 5 Years | 10.01 | 10.25 | 1.33 | 4.78 | 382,291 | -7.82 | -78.12% |
Marker Therapeutics Description
| Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart. |
